Prostate Cancer

A 63-year-old African-American male presents to the emergency department with sudden onset of painless gross hematuria for one day. He reports dark red urine with clots causing occasional dysuria, difficulty emptying, and light-headedness.

Patients with CVD taking abiraterone or enzalutamide have a 43% higher risk of hospitalization, according to a recent study.

A survey of low-risk prostate cancer patients found men who choose active surveillance over definitive treatment have similar mental health outcomes.

Analyses based on number needed to treat benefit show that the overall survival benefit is similar when using abiraterone acetate (ZYTIGA), enzalutamide (XTANDI), or sipuleucel-T (Provenge) to treat men with chemotherapy-naïve metastatic castration-resistant prostate cancer. The data, however, favor sipuleucel-T for having the lowest direct cost.

Do you feel that DRE is still a relevant tool in the management of prostate cancer? Take our latest poll and let us know.

Mark Frydenberg, MD, of Australia's Monash University, discusses whether multiparametric MRI is ready to be used as a screening modality for prostate cancer.

In this interview, Mark Frydenberg, MD, discusses the evolution of PET scanning, its clinical indications, its advantages and drawbacks, and key questions that remain about its use.

"While much work is still to be done, we have excellent evidence that there is a beneficial class-like effect for the androgen inhibitors enzalutamide, apalutamide, and darolutamide used within the current definition of men with M0 CPRPC," write Michael Cookson, MD, and Tony Rodriguez, MD.

The magnetic resonance imaging pathway is the most accurate diagnostic strategy for detecting clinically significant prostate cancer, according to a recent literature review.

Researchers have identified a urine biomarker that noninvasively helps detect aggressive prostate cancer about as accurately as tissue-based prognostic markers, according to a recent study.

Neoadjuvant chemohormonal therapy warrants consideration in the management of men undergoing radical prostatectomy for clinically localized high-risk prostate cancer, said James Eastham, MD, at the American Society of Clinical Oncology annual meeting in Chicago.

Results of a phase III trial show the benefit of darolutamide (Nubeqa) in reducing the risk of metastases or death compared with placebo in men with nonmetastatic castration-resistant prostate cancer.

Race does not affect oncologic response to treatment with docetaxel (Taxotere)/prednisone in men with metastatic castrate-resistant prostate cancer, according to research presented at the American Society of Clinical Oncology annual meeting in Chicago.

18F-DCFPyL PET/CT imaging demonstrated excellent performance in identifying regional or distant metastases in men with prostate cancer in the prospective OSPREY study.

A pivotal phase II trial of a novel MRI-guided ultrasound ablation treatment exceeded its primary efficacy endpoint of PSA decline in men with organ-confined prostate cancer.

These six questions are meant to test your knowledge of the updates to the AUA's treatment guideline for castration-resistant prostate cancer.

"This report brings to light an often-suspected but previously undocumented clinical issue in great and alarming detail," says Badar M. Mian, MD.

Data from a recent study suggest that exposure to dust from the World Trade Center attack has resulted in an inflammatory cascade that led to the development of high-grade prostate cancer in first responders.

“This study supports an association between body fat distribution and prostate cancer risk,” says researcher Barbra Dickerman, PhD.

A significant proportion of men who progress radiologically while on the androgen receptor inhibitor enzalutamide (XTANDI) do not meet standard criteria for PSA progression, reported Fred Saad, MD.

"Deciding what care is appropriate is already extraordinarily difficult but will be a growing problem for the next generation of physicians and society," writes Peter C. Albertsen, MD.

Integration of tumor genetic testing and genomically-informed therapies into clinical practice for patients with advanced prostate cancer are featured in updated National Comprehensive Cancer Network guidelines on the management of prostate cancer (version 2.2019).

Men with low levels of free testosterone 3 months after undergoing radical prostatectomy could face increased chance of early recurrence of prostate cancer, according to researchers from the University of California Irvine.

More research is needed to determine the value of using magnetic resonance imaging to predict pathology outcomes following radical prostatectomy, according to a study presented at the AUA annual meeting in Chicago.